Filtered By:
Vaccination: Malaria Vaccine

This page shows you your search results in order of date. This is page number 3.

Order by Relevance | Date

Total 69 results found since Jan 2013.

A Bivalent Conjugate Vaccine for Malaria and Typhoid Prophylaxis
Malaria is the single leading cause of mortality, especially among children in the developing world. Typhoid fever, caused by infection withSalmonella typhi, is known to be endemic with malaria and causes its own significant disease burden. Scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have developed a novel bivalent vaccine candidate that may effectively prevent malaria and typhoid. This approach significantly enhances immune response to the Pfs25 Malaria transmission blocking antigen and produces a robust immune response againstSalmonella typhi...
Source: NIH OTT Licensing Opportunities - March 1, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Experimental Malaria Vaccine Provides Durable Protection Against Multiple Strains in NIH Clinical Trial
An experimental malaria vaccine protected healthy subjects from infection with a malaria strain different from that contained in the vaccine, according to a study published this week in the Proceedings of the National Academy of Sciences (PNAS). The research was conducted by scientists at the University of Maryland School of Medicine and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
Source: University of Maryland School of Medicine News Headlines - February 24, 2017 Category: Universities & Medical Training Source Type: news

NIH initiates Phase I trial of AGS-v to prevent mosquito-transmitted diseases
National Institutes of Health (NIH) division the National Institute of Allergy and Infectious Diseases (NIAID) has initiated a Phase I clinical trial of vaccine AGS-v to prevent a range of mosquito-transmitted diseases such as the Zika virus, malaria …
Source: Drug Development Technology - February 22, 2017 Category: Pharmaceuticals Source Type: news

Experimental malaria vaccine offers durable protection against many strains in NIH trial
(NIH/National Institute of Allergy and Infectious Diseases) An investigational malaria vaccine has protected a small number of healthy US adults from infection with a malaria strain different from that contained in the vaccine, according to a study published today in the Proceedings of the National Academy of Sciences (PNAS). The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, sponsored and co-conducted the Phase 1 clinical trial.
Source: EurekAlert! - Infectious and Emerging Diseases - February 21, 2017 Category: Infectious Diseases Source Type: news

NIH begins study of vaccine to protect against mosquito-borne diseases
(NIH/National Institute of Allergy and Infectious Diseases) The National Institute of Allergy and Infectious Diseases, has launched a Phase 1 clinical trial to test an investigational vaccine intended to provide broad protection against a range of mosquito-transmitted diseases, such as Zika, malaria, West Nile fever and dengue fever, and to hinder the ability of mosquitoes to transmit such infections. The study, conducted at the NIH Clinical Center in Bethesda, Maryland, will examine the vaccine's safety and ability to generate an immune response.
Source: EurekAlert! - Infectious and Emerging Diseases - February 21, 2017 Category: Infectious Diseases Source Type: news

Study: Experimental malaria vaccine plus chloroquine protects against controlled infection
(NIH/National Institute of Allergy and Infectious Diseases) An experimental malaria vaccine strategy known as PfSPZ-CVac, together with antimalarial medication, protected all nine clinical trial volunteers given three high-dose vaccinations, according to study results published today in Nature.
Source: EurekAlert! - Infectious and Emerging Diseases - February 15, 2017 Category: Infectious Diseases Source Type: news

Investigational malaria vaccine shows considerable protection in adults in malaria season
(NIH/National Institute of Allergy and Infectious Diseases) An investigational malaria vaccine given intravenously was well-tolerated and protected a significant proportion of healthy adults against infection with Plasmodium falciparum malaria -- the deadliest form of the disease -- for the duration of the malaria season, according to new findings published in the Feb. 15th issue of the journal Lancet Infectious Diseases. The study participants live in Mali, Africa, where they are naturally exposed to the parasite.
Source: EurekAlert! - Infectious and Emerging Diseases - February 15, 2017 Category: Infectious Diseases Source Type: news

2016 Research Highlights — Clinical Breakthroughs
NIH accomplishments in the prevention, diagnosis, and treatment of human disease. These include a way to restore blood sugar control in type 1 diabetes, food allergy prevention, and an experimental malaria vaccine.
Source: NIH Research Matters from the National Institutes of Health (NIH) - December 19, 2016 Category: Consumer Health News Source Type: news

It's a lot of work to be nonallergic
Edward Jenner developed the first successful vaccine based on the observation that persons exposed to poxvirus pathogens who did not succumb to the disease became protected from further encounters.1 In more recent trials, much has been learned about correlates of health and protection from controlled challenges in patients with infectious diseases as diverse as influenza and malaria, in which the study of exposed subjects who mount an appropriate immune response might hold the key to development of treatment and vaccination alike.
Source: Journal of Allergy and Clinical Immunology - December 16, 2016 Category: Allergy & Immunology Authors: Alessandro Sette, V éronique Schulten Tags: Editorial Source Type: research

Enteric fever in a British soldier from Sierra Leone
We report the case of a soldier who developed typhoid despite appropriate vaccination and field hygiene measures, which began 23 days after returning from a deployment in Sierra Leone. The incubation period was longer than average, symptoms started 2 days after stopping doxycycline for malaria chemoprophylaxis and initial blood cultures were negative. The Salmonella enterica serovar Typhi eventually isolated was resistant to amoxicillin, co-amoxiclav, co-trimoxazole and nalidixic acid and had reduced susceptibility to ciprofloxacin. He was successfully treated with ceftriaxone followed by azithromycin, but 1 ...
Source: Journal of the Royal Army Medical Corps - May 25, 2016 Category: Journals (General) Authors: Osborne, L. G., Brown, M., Bailey, M. S. Tags: Infectious diseases, Epidemiologic studies, Immunology (including allergy) Case report Source Type: research

Global Health: A Malaria Vaccine Has Some Success in Testing
An experimental vaccine tested in varying doses provided 55 percent protection for one year to a few volunteers, according to a study released Monday.
Source: NYT - May 9, 2016 Category: American Health Authors: DONALD G. McNEIL Jr. Tags: Vaccination and Immunization Malaria National Institute of Allergy and Infectious Diseases Nature Medicine (Journal) Sanaria Inc Seder, Robert A. Source Type: news

Investigational malaria vaccine protects healthy US adults for more than one year
(NIH/National Institute of Allergy and Infectious Diseases) An experimental malaria vaccine protected a small number of healthy, malaria-naïve adults in the US for more than one year after immunization, according to results from a NIAID-supported Phase 1 trial. NIAID researchers and University of Maryland School of Medicine collaborators conducted the clinical evaluation of the vaccine, which involved immunization and exposing willing healthy adults to the malaria-causing parasite in a controlled setting. The PfSPZ Vaccine was developed and produced by Sanaria Inc.
Source: EurekAlert! - Medicine and Health - May 9, 2016 Category: Global & Universal Source Type: news

U.S. Officials Warn Zika 'Scarier' Than Initially Thought
By Timothy Gardner and Jeff Mason WASHINGTON (Reuters) - Top health officials expressed heightened concern on Monday about the threat posed to the United States by the Zika virus, saying the mosquito that spreads it is now present in about 30 states and hundreds of thousands of infections could appear in Puerto Rico. At a White House briefing, they stepped up pressure on the Republican-led Congress to pass approximately $1.9 billion in emergency funding for Zika preparedness that the Obama administration requested in February. "Everything we look at with this virus seems to be a bit scarier than we initially thought," said...
Source: Healthy Living - The Huffington Post - April 12, 2016 Category: Consumer Health News Source Type: news

Current status of synthetic hemozoin adjuvant: A preliminary safety evaluation.
Abstract Although adjuvants are a "must-have" component of successful vaccines, there are very few adjuvants licensed for use in humans, there is therefore an urgent need to develop new and safer adjuvants. Synthetic hemozoin (sHZ), a chemical analog of hemozoin which is produced by the malaria parasite, exhibits a potent adjuvant effect which enhances antigen-specific immune responses to vaccines. The potency of sHZ adjuvanticity is not limited to malaria specific vaccines, it has also been demonstrated to be effective in influenza and dog allergy models. While the synthesis of uniformly sized sHZ with consistent...
Source: Vaccine - March 11, 2016 Category: Allergy & Immunology Authors: Lee MS, Igari Y, Tsukui T, Ishii KJ, Coban C Tags: Vaccine Source Type: research